Duke University Medical Center scientists inked a research collaboration to use WaferGen Biosystems’ SmartChip™ Real-Time PCR System in cancer-related genotyping.  WaferGen believes the SmartChip Real-Time PCR System will be the first platform to combine the high-throughput capability and cost efficiencies of existing microarrays with the sensitivity and accuracy of real-time PCR. 


Under terms of the collaboration, the laboratory of John A. Olson Jr., M.D., Ph.D., and Jeffrey R. Marks, Ph.D., at the Institute for Genome Sciences and Policy will conduct genotyping projects using the technology to validate SNPs related to breast cancer.  Additionally, researchers will aim to examine the impact the validated SNPs have on patients’ disease prognosis and response to treatment.

Previous articleBayer Pays Ardea $35M for Its Anticancer MEK Inhibitors
Next articlePro-Pharmaceuticals Inks Marketing Deal with Perceptive in Central and South America